Immunome, Inc.

Immunome, Inc.

IMNM·NASDAQ

$19.78

-0.15%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.89B
EPS-2.4300
P/E Ratio-8.14
Earnings Date08/05/2026

imnm

Gross Profit

Last Annual Value

3.99M

3-Year CAGR

%

5-Year CAGR

49%

10-Year CAGR

25%

Immunome, Inc.

Immunome, Inc. Competitors Analysis of Gross Profit

IMNM · NASDAQ
CompanyGross Profit
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
3.99M
-34.2%N/AN/A 
9.94M
-41.6%N/AN/A
51.75M
23.8%14.6%N/A
2.37M
-0.1%N/AN/A
-2.40M
N/AN/AN/A
1.50M
N/AN/AN/A
-468.00K
N/AN/AN/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
-4.14M
N/AN/AN/A
-171.65M
N/AN/AN/A
Immunome, Inc.

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.78, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

Intrinsic Value
Current Price: $19.78